SUBJECT

Principles of health economic evaluation

lecture

master

Faculty of Social Sciences

Health Policy, Planning and Financing (Specialization in Health Economics) MSc (part time)

4

Semester 2

Spring semester

Students should be familiar with the basics of economic evaluations. They should learn the main types of economic evaluations, the major steps of conducting economic evaluations. They should understand the applicability of economic evaluation in health care and health technology assessment to improve the allocative efficiency of health care systems.

• Michael F. Drummond, Mark J. Sculpher, George W. Torrance, Bernie J. O'Brien, and Greg L. Stoddart.: Methods for the Economic Evaluation of Health Care Programmes.
• Alastair M. Gray, Philip M. Clarke, Jane L. Wolstenholme, and Sarah Wordsworth: Applied Methods of Cost-effectiveness Analysis in Healthcare.
• Johanesson, Magnus: Theory and Methods of Economic Evaluation of Health Care. Kluwer Akademic Publishers, 1996 – this is not on the reading list but provides a very useful summary of various issues we discuss during the module.
• In: Handbook of Health Economics. Volume 2, 2011.
• Meltzer David O, Smith Peter C.: Theoretical Issues Relevant to the Economic Evaluation of Health Technologies. Pages 433–448
• Brouwer WB1, Culyer AJ, van Exel NJ, Rutten FF.: Welfarism vs. extra-welfarism.J Health Econ. 2008 Mar;27(2):325-38.
• In: (eds) Michael F. Drummond, Mark J. Sculpher, George W. Torrance, Bernie J. O'Brien, and Greg L. Stoddart.: Methods for the Economic Evaluation of Health Care Programmes. Third Edition, June 2005.
• Ch. 2 Basic types of economic evaluation. pg. 6-26
• In: (eds) Michael F. Drummond, Mark J. Sculpher, George W. Torrance, Bernie J. O'Brien, and Greg L. Stoddart.: Methods for the Economic Evaluation of Health Care Programmes. Third Edition, June 2005.
• Ch. 7 Cost-benefit analysis. pg. 205-231
• In: (eds) Alastair M. Gray, Philip M. Clarke, Jane L. Wolstenholme, and Sarah Wordsworth: Applied Methods of Cost-effectiveness Analysis in Healthcare., 2011, Handbooks in Health Economic Evaluation, volume 3.
• Chapter 2. Economic evaluation in health care. pg 7-39.
• Weinstein, M.; Zeckhauser, R. J. [1973]: Critical Ratios and Efficient Allocation. Journal of Public Economics. 2, 147–157.
• Zong X.,Sun l. [2011]: A review of the methods for determining cost effectiveness threshold in health care. Journal of Chinese Pharmaceutical Sciences. 542-548
• In: (eds) Alastair M. Gray, Philip M. Clarke, Jane L. Wolstenholme, and Sarah Wordsworth: Applied Methods of Cost-effectiveness Analysis in Healthcare., 2011, Handbooks in Health Economic Evaluation, volume 3.
• Chapter 2. Economic evaluation in health care. pg 7-39.
• Josephine A. Mauskopf, Sean D. Sullivan, Lieven Annemans, Jaime Caro,
• C. Daniel Mullins, Mark Nuijten, Ewa Orlewska, John Watkins, Paul Trueman: Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis. Volume 10, Number 5, 2007. Value in health
• In: Handbook of Health Economics. Volume 2, 2011.
• Meltzer David O, Smith Peter C.: Theoretical Issues Relevant to the Economic Evaluation of Health Technologies. Pages 433–448
• ~Alan M. Garber, Mark J. Sculpher: Cost Effectiveness and Payment Policy.
• In: (eds) Alastair M. Gray, Philip M. Clarke, Jane L. Wolstenholme, and Sarah Wordsworth: Applied Methods of Cost-effectiveness Analysis in Healthcare., 2011, Handbooks in Health Economic Evaluation, volume 3.
• Chapter 5. Measuring, valuing and analysing health outcomes. pg 81-112.
• In: (eds) Michael F. Drummond, Mark J. Sculpher, George W. Torrance, Bernie J. O'Brien, and Greg L. Stoddart.: Methods for the Economic Evaluation of Health Care Programmes. Third Edition, June 2005.
• Ch. 6 Cost-utility analysis. pg. 137-204
• International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use: General Considerations For Clinical Trials pp 3-12. (types of non-clinical and clinical trials, involvement of special populations, design aspects)
• FDA Guidance for Industry E 10: Choice of Control Group and Related Issues in Clinical Trials pp 3-6, 9-13, 14-30 (application of placebo and control, blinding)
• WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects (as amended in 2013) pp1-5 (ethical principles of human researches)
• Röhrig B. et al. Types of Study in Medical Research. Deutsches Ärzteblatt International 2009; 106(15): 262–8 (types of medical researches)
• Snapinn S. M. Noninferiority trials Curr Control Trials Cardiovasc Med 2000, 1:19–21 (conception of non-inferiority trials)
• Aronson J. K. What is a clinical trial? British Journal of Clinical Pharmacology pp 1-3
• In: (eds) Alastair M. Gray, Philip M. Clarke, Jane L. Wolstenholme, and Sarah Wordsworth: Applied Methods of Cost-effectiveness Analysis in Healthcare., 2011, Handbooks in Health Economic Evaluation, volume 3.
• Chapter 6. Defining, measuring and valuing costs. pg 119-143.
• ~Chapter 7. Analysing costs. pg 143-178.
• In: Drummond, Michael and McGuire, Alistair, (eds.) Economic Evaluation in Health Care : Merging Theory With Practice. Oxford University Press, Oxford, UK.
• Glick H, Polsky, D, Schulman K.: Trial based economic evaluations: an overview of design. Pg 113-140
• In:(eds) Alastair M. Gray, Philip M. Clarke, Jane L. Wolstenholme, and Sarah Wordsworth: Applied Methods of Cost-effectiveness Analysis in Healthcare., 2011, Handbooks in Health Economic Evaluation, volume 3.
• Chapter 8. Decision analytic modelling: decision trees. pg 179-210.
• In:(eds) Alastair M. Gray, Philip M. Clarke, Jane L. Wolstenholme, and Sarah Wordsworth:
• Applied Methods of Cost-effectiveness Analysis in Healthcare., 2011, Handbooks in Health Economic Evaluation, volume 3
• Chapter 9. Decision analytic modelling: Markov models. pg 211-248.
• Nataša Bogavac-Stanojević, Violeta Dopsaj, Zorana Jelić-Ivanović, Dragana Lakić, Dragan Vasić, Guenka Petrova: Economic evaluation of different screening alternatives for patients with clinically suspected acute deep vein thrombosis. Biochemia Medica 2013;23(1):96–106